Check 35,000+ stocks against 26 valuation models and 37 quality factors

ACADIA Pharmaceuticals Inc (ACAD) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of ACADIA Pharmaceuticals Inc $20.43, price $25.43, upside -19.7%, quality 63 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN US0042251084

Some data Sep 23, 2026

ACADIA Pharmaceuticals Inc

ACAD · US

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value $20.43 · Overvalued (−20%)

!Quality 63/100

!Mixed Growth (revenue 5y +19.4 %/yr)

✓Highly profitable · 34.3% net margin (TTM)

✓Low debt · generates free cash flow

✓Ranks above peers (9/14)

!Moderate moat 59/100

!Insider activity 44/100

!Evidence only medium, so the estimate is less certain

!The models disagree: range $11.02 to $35.72

!Weak on valuation: 7 out of 100

26 models, one by oneBear $11.02 to bull $35.72 Growth analysisrevenue history, year by year Quality 63/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch ACADIA Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $13.01 – $33.47 · fair‑value band $11.02 – $35.72 · the $25.43 price screens above the $20.43 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow ACADIA Pharmaceuticals in your weekly email

Every Wednesday you see whether ACADIA Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Stock analysis

ACADIA Pharmaceuticals Inc (ACAD) currently trades at $25.43, while our model-based Fair Value estimate is $20.43, implying the stock looks roughly 24.5% overvalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of $106.09 per share, and 9 of the 24 models we run sit above the $25.43 price.

Bear case: the Asset-Based group reads lowest at $4.80, and 15 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: $11.02 (bear) to $35.72 (bull), the price of $25.43 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

ACADIA Pharmaceuticals Inc reported revenue of $1.1B in FY2025 versus $484M in FY2021, a compound +22.0%/yr. Reported net income was $391M in FY2025.

Key figures

Market cap $4.4B · P/E ratio 11.5 · P/S ratio 4.20 · EPS (TTM) $2.21 · Net margin 36.5% · Return on equity 37.3% · Return on assets (EBIT) −9.2% · Operating margin −1.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic.

The share trades about 17% below its 52-week high and 27% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −20%, ACAD screens richer than that median.

Fair Value models

Bear $11.02 Fair Value $20.43 Bull $35.72

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($1.62 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $11.36 $16.93 $34.29 74

EPV $6.05 $6.84 $7.52 74

Growth DCF $10.73 $19.48 $33.59 73

All 24 models by family

DCF Models

FCF DCF $11.36 $16.93 $34.29 74

Owner Earnings $36.07 $78.68 $164.84 68

5Y Revenue Exit $8.39 $13.42 $23.91 68

5Y EBITDA Exit $9.27 $15.18 $26.76 70

5Y P/E Exit $31.81 $76.54 $138.64 65

10Y Revenue Exit $9.16 $18.00 $23.36 64

10Y EBITDA Exit $10.02 $19.83 $36.56 63

10Y P/E Exit $26.10 $67.26 $137.51 57

Earnings-Based

Graham-Dodd $15.53 $108.28 $151.96 61

Lynch FV $55.94 $79.92 $103.89 59

PEG = 1.0 $55.94 $79.92 $103.89 55

EPV $6.05 $6.84 $7.52 74

Multiples

P/E Multiple $37.68 $50.23 $62.79 63

P/S Multiple $16.43 $21.90 $27.38 58

P/B Multiple $24.19 $32.26 $40.32 55

EV/EBIT $8.84 $11.44 $14.04 66

EV/EBITDA $8.19 $10.57 $12.95 67

EV/Revenue $6.61 $8.99 $11.38 54

Asset-Based

NCAV (Graham) $3.58 $4.80 $7.17 54

Growth DCF

Growth DCF $10.73 $19.48 $33.59 73

Rev-Margin DCF $9.14 $15.20 $27.92 67

Economic Profit

Residual Income $15.97 $22.35 $184.19 56

ROIC Compounder $6.05 $6.84 $8.11 70

Growth Earnings

Growth-Adj P/E $74.26 $106.09 $137.91 65

Open the full fair value analysis →

Notify me when ACAD reaches fair value

Put ACAD on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 63/100

Of which business quality 65 · Market factors (momentum, volatility) 57

Profitability 89

Margins and returns on capital today

Quality Growth 57

Are margins and returns improving?

Cashflow 48

Earnings quality: real cash, not paper profit

Fin. Strength 88

Balance sheet, leverage, solvency risk

Investment 33

Disciplined investing over empire-building

Low Volatility 63

Calm price path (market factor)

Momentum 60

Price trend over the last 3–12 months (market factor)

52W Momentum 44

Distance to the 52-week high (market factor)

Net Issuance 57

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 77/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+11.9%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+27.5%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+19.4%

Start year 2020 (pandemic). Over 10 years: +165.7% a year

Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+24.7%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−64.9% (2020) → 9.8% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year

not computed

Growth Forecast

A lot of optimism in the price

The price assumes about as much growth as the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+17.9%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+11.5%

Yearly sales growth analysts expect, extended to five years.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +15.2% a year for the price and +8.9% for the forecasts.

Forecast 2026 (sales)+15.8%

Forecast 2027 (sales)+12.4%

Projected 2028 (sales)+11.1%

Projected 2029 (sales)+9.8%

Projected 2030 (sales)+8.5%

ACAD screens 24% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive

Recent news coverage is more positive than average.

Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report? Yahoo Finance · Sep 3, 2026
AcadeMedia (OM:ACAD) Reports Stronger Results, Is The 19% Upside Still There? Yahoo Finance · Aug 31, 2026
Acadia Gets European Commission Nod for Daybu in Rett Syndrome Yahoo Finance · Aug 24, 2026
Biotech Stocks At 52-Week Highs - BIVI +22%, XNCR, ANRO, HAE, ACAD Nasdaq · Aug 13, 2026

Compare ACADIA Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks

Beats the industry median on 7/13 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 63 · Top 25%

Fair Value upside −23% · Above median

Profitability

Return on equity (TTM) 37% · Top 25%

Return on assets 4% · Top 25%

Net margin (TTM) 34% · Top 25%

Operating margin (TTM) −2% · Below median

Growth and dividend

Revenue growth 10% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 11.5× · Cheapest 25%

P/B 3.69× · Priciest 25%

P/S (TTM) 4.13× · Pricier than median

P/FCF 43.0× · Priciest 25%

EV/EBITDA 46.9× · Priciest 25%

PEG 50.86× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)7 · sector 0

FUTURE (revenue growth)49 · sector 0

PAST (return on equity)100 · sector 0

HEALTH (low debt)100 · sector 97

DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	$514.99	$566.49	+10%
Regeneron Pharmaceuticals, Inc REGN	$803.90	$1,252	+56%
argenx SE ARGX	$963.79	$918.60	−5%
Samsung Biologics Co 207940	1,366,000 KRW	1,502,600 KRW	+10%
CSL Limited CSL	A$179.24	A$197.16	+10%
Alnylam Pharmaceuticals, Inc ALNY	$251.65	$218.36	−13%
Royalty Pharma plc RPRX	$58.52	$24.22	−59%
Celltrion, Inc 068270	177,400 KRW	74,519 KRW	−58%
BeOne Medicines AG ONC	$368.08	$280.94	−24%
BioNTech SE BNTX	$100.87	$63.62	−37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ACADIA Pharmaceuticals Inc · Fair Value
$20.43 −24%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/ACAD" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">ACADIA Pharmaceuticals Inc · Fair Value</span><br><b style="font-size:20px">$20.43</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−24%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "ACADIA Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/ACAD

Frequently asked questions

Is ACADIA Pharmaceuticals Inc (ACAD) overvalued or undervalued?

As of Sep 23, 2026, our model estimates a fair value of $20.43 versus a price of $25.43, about −20% upside (overvalued).

What is the fair value of ACAD?

Our model-based fair value for ACADIA Pharmaceuticals Inc is $20.43 (as of Sep 23, 2026), built from audited fundamentals. The current price: $25.43.

What is the quality score of ACAD?

ACADIA Pharmaceuticals Inc has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for ACADIA Pharmaceuticals Inc (ACAD)?

Our model-based price target is the fair value of $20.43 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario $11.02, optimistic scenario $35.72. It is a calculation from audited fundamentals, not an analyst target.

What is the ACADIA Pharmaceuticals Inc stock forecast for 2026?

Our models put fair value at $20.43, about −20% upside versus a price of $25.43 (overvalued). Cautious scenario $11.02, optimistic scenario $35.72. The calculation is refreshed regularly with new filings.

What is the revenue of ACADIA Pharmaceuticals Inc (ACAD)?

ACADIA Pharmaceuticals Inc reported trailing-twelve-month revenue of about $1.1B (latest available figure, as of Sep 23, 2026).

What growth is priced into ACADIA Pharmaceuticals Inc (ACAD)?

For today's price to be fair in a discounted-cash-flow model, ACADIA Pharmaceuticals Inc would have to grow free cash flow by +17.9 % per year for five years (discount rate 9.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.4 % per year. As of Sep 23, 2026.

What discount rate (WACC) does the fair value of ACAD use?

Our models discount ACADIA Pharmaceuticals Inc at 9.2 %: a base by market capitalisation (mid), damped by beta 0.80, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ACADIA Pharmaceuticals Inc that is +17.9 % per year a year over ten years, using the same discount rate (9.2 %) and the same formula as our fair value.

How much growth has ACADIA Pharmaceuticals Inc (ACAD) delivered so far?

Over the past 5 years revenue at ACADIA Pharmaceuticals Inc grew +19.4 % a year. The price currently implies +17.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of ACADIA Pharmaceuticals Inc (ACAD) growing?

The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into ACADIA Pharmaceuticals Inc (+17.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of ACADIA Pharmaceuticals Inc (ACAD)?

The free-cash-flow yield on the price is 2.41 %: that much free cash flow ACADIA Pharmaceuticals Inc produces per unit of market value. When it exceeds the discount rate of our models (9.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of ACADIA Pharmaceuticals Inc (ACAD)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ACADIA Pharmaceuticals Inc it is $20.43 per share (as of Sep 23, 2026), against a price of $25.43. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is ACADIA Pharmaceuticals Inc stock overvalued or undervalued in 2026?

As of Sep 23, 2026, ACAD trades above its calculated fair value: price $25.43, fair value $20.43, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of ACAD?

No. The price is what the market pays today ($25.43); the fair value is what the company's own numbers justify ($20.43). For ACADIA Pharmaceuticals Inc the two are $5.00 per share apart. That gap is exactly why we show both numbers side by side.

How much is ACADIA Pharmaceuticals Inc worth?

The market values ACADIA Pharmaceuticals Inc at about $4.4B (market capitalisation, as of Sep 23, 2026). Per share that is $25.43; our models calculate a fair value of $20.43 per share.

What do the bullish and bearish scenarios say about ACAD?

Our models span a range for ACADIA Pharmaceuticals Inc: cautious scenario $11.02, base $20.43, optimistic $35.72 per share (as of Sep 23, 2026, price $25.43). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of ACAD?

ACADIA Pharmaceuticals Inc trades at a price-to-earnings ratio of 11.5 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $20.43 is built from several models across several years. Other multiples: PEG 50.9, P/B 3.7, P/S 4.1, EV/EBITDA 46.9.

What is the PEG ratio of ACAD?

The PEG ratio of ACADIA Pharmaceuticals Inc is 50.86 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.

How solid is the balance sheet of ACADIA Pharmaceuticals Inc (ACAD)?

Balance-sheet figures for ACADIA Pharmaceuticals Inc (as of Sep 23, 2026): return on equity 37.3%. They feed the Quality Score of 63/100, which measures business quality independently of the share price.

How far is ACAD from its 52-week high?

ACADIA Pharmaceuticals Inc trades at $25.43, about 17% below its 52-week high of $30.57 and 27% above the low of $20.06 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $20.43 is for.

Which stocks are comparable to ACADIA Pharmaceuticals Inc?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is ACADIA Pharmaceuticals Inc stock attractive at the current price?

The data as of Sep 23, 2026: price $25.43, calculated fair value $20.43 (−20%), Quality Score 63/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of ACAD calculated?

We run ACADIA Pharmaceuticals Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $20.43, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.1 % above its aggregate fair value. ACADIA Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of ACADIA Pharmaceuticals Inc (ACAD)?

The closing price on Sep 23, 2026 was $25.43. Our model-based fair value is $20.43, about −20% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with ACADIA Pharmaceuticals Inc right now?

The model range is unusually wide ($11.02 to $35.72). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of ACADIA Pharmaceuticals Inc

How large is the market capitalisation of ACADIA Pharmaceuticals Inc (ACAD)?

The market capitalisation of ACADIA Pharmaceuticals Inc is $4.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of ACADIA Pharmaceuticals Inc (ACAD)?

The price-to-sales ratio of ACADIA Pharmaceuticals Inc is 4.20 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of ACADIA Pharmaceuticals Inc (ACAD)?

Earnings per share at ACADIA Pharmaceuticals Inc are $2.21 (price ÷ EPS = P/E 11.5). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of ACADIA Pharmaceuticals Inc (ACAD)?

The net margin of ACADIA Pharmaceuticals Inc is 36.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of ACADIA Pharmaceuticals Inc (ACAD)?

The return on equity (ROE) of ACADIA Pharmaceuticals Inc is 37.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of ACADIA Pharmaceuticals Inc (ACAD)?

On an EBIT basis the return on assets of ACADIA Pharmaceuticals Inc is −9.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of ACADIA Pharmaceuticals Inc (ACAD)?

The operating margin of ACADIA Pharmaceuticals Inc is −1.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at ACADIA Pharmaceuticals Inc (ACAD)?

Revenue at ACADIA Pharmaceuticals Inc is growing +9.7% versus a year earlier (3y avg +27.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at ACADIA Pharmaceuticals Inc (ACAD)?

Earnings per share at ACADIA Pharmaceuticals Inc are growing −81.8% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does ACADIA Pharmaceuticals Inc (ACAD) hold?

ACADIA Pharmaceuticals Inc holds more cash than debt, $126M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch ACADIA Pharmaceuticals Inc in the live analysis

One click puts ACADIA Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.